The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Verona Pharma Plc (NASDAQ: VRNA) rallied about 20% on Wednesday after Merck & Co Inc (NYSE: MRK) said it will buy the ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could be a steal of a deal.

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS≥1) ...

In Merck’s case, worries over rising competition from so-called ‘biosimilar’ generic products, which approximate the biological chemical structure of branded medicines, is behind much of the ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

The safety profile of KEYTRUDA plus Trodelvy in this study was consistent with the known safety profile of each agent. No new safety signals were identified with the combination.

May 31 (Reuters) - Gilead Sciences' (GILD.O) Trodelvy in combination with Merck's (MRK.N) blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35 ...

Patients who received Keytruda were more likely to have at least a 90% reduction in the size of their tumor before undergoing surgery, compared to those in the control group, the researchers found.

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.